GlassScriptPhysician profile
Kevin Iseman
NPI 1447229729
$1,479.50
in general payments reported to CMS, 2019-2025
23 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.26 · 2023: $198 · 2024: $1,144 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,452 · Entertainment: $14.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,451.89 |
| Entertainment | $14.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $327.95 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $205.11 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $133.00 | 2024 | Airsupra, Farxiga, Breztri |
| Abbott Laboratories | $121.66 | 2024-2025 | Freestyle Libre 3 |
| Pfizer INC. | $88.66 | 2024 | |
| Amgen INC. | $79.73 | 2023-2024 | Evenity, Prolia, Otezla |
| Dexcom, INC. | $72.85 | 2024 | Dexcom G6 Transmitter |
| Harmony Biosciences LLC | $64.51 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.97 | 2024 | Trintellix |
| Insightec,INC | $42.62 | 2024 | Exablate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.75 | 2024 | Xifaxan |
| Astellas Pharma US INC | $33.97 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $33.56 | 2023 | Inspire |
| Glaxosmithkline, LLC. | $32.09 | 2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $30.55 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Resmed Corp | $19.77 | 2023 | |
| Abbvie INC. | $18.68 | 2024 | |
| Philips North America LLC | $18.08 | 2024 | (Ck6) Holter |
| Corcept Therapeutics | $17.03 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $15.12 | 2024 | Nexletol |
| Optos, INC. | $14.35 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Fisher & Paykel Healthcare INC | $13.26 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.23 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Iseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.